Opinion

Video

Patient with R/R CLL Treated with 2L Venetoclax Therapy

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Video content above is prompted by the following questions:

  • Please present your clinical case of an elderly patient with R/R CLL who receives second-line fixed-duration therapy with venetoclax.
  • Please describe your initial impressions of this case. How might you have treated this patient in your practice?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
David C. Fisher, MD
2 KOLs are featured in this series.
Related Content
Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 4th 2024

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.
October 29th 2024

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens